Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + celecoxib
- Development stage
- Unknown
- Lead developer
- Johnson Matthey
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination of carboplatin, an organoplatinum antineoplastic alkylating agent, and celecoxib, a selective COX-2 inhibitor. Carboplatin acts as a DNA cross-linking agent that interferes with DNA replication, while celecoxib reduces inflammation by inhibiting COX-2 enzyme. However, research indicates that celecoxib may antagonize the cytotoxic effects of carboplatin by reducing intracellular carboplatin accumulation and inhibiting carboplatin-induced apoptosis.
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)DNA
Beyond the preview
Go deeper on carboplatin + celecoxib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + celecoxib.